Background: Recurrent miscarriage (RM), defined as three or more consecutive losses during the first trimester of pregnancy, affects 1%–2% of fertile couples. It is a common public health reproductive burden causing both physical and emotional distress. To date, there is no treatment whose benefit has been proved.
Aim: To investigate whether HCQ (orally administrated before conception until ten weeks of gestational age) would improve the live birth rate of 15% or more in women with the previous RM.
Patient and method: We conducted a double-blind, randomized placebo-controlled trial on 300 female patients suffering from recurrent miscarriages. At randomization, the minimization method will be used to balance between the two groups and two main determinants of miscarriage recurrence: maternal age (≤35 or >35 years) and the number of previous losses (3 or ≥4).
Results: The current study showed that 30% of study female patients completed their pregnancy after taking hydroxychloroquine (HCQ), while 70% of them did not complete the pregnancy. We found a statistically significant difference (P = 0.001) regarding the mean age between cases and controls.
Conclusion: We obtained some significant positive results regarding the orally administrated HCQ usage to improve the live birth in women suffering from recurrent miscarriages.